Interactive process mining of cancer treatment sequences with melanoma real-world data

被引:2
作者
Wicky, Alexandre [1 ]
Gatta, Roberto [1 ,2 ]
Latifyan, Sofiya [3 ]
Micheli, Rita De [3 ]
Gerard, Camille [1 ]
Pradervand, Sylvain [1 ]
Michielin, Olivier [1 ,4 ]
Cuendet, Michel A. [1 ,4 ,5 ]
机构
[1] Lausanne Univ Hosp, Precis Oncol Ctr, Dept Oncol, Lausanne, Switzerland
[2] Univ Brescia, Dipartimento Sci Clin & Sperimentali, Brescia, Italy
[3] Lausanne Univ Hosp, Dept Oncol, Med Oncol, Lausanne, Switzerland
[4] Univ Lausanne, Swiss Inst Bioinformat, Lausanne, Switzerland
[5] Weill Cornell Med, Dept Physiol & Med, New York, NY 10021 USA
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
precision oncology; process mining; real-world data; melanoma; immunotherapy; targeted treatment; treatment sequence; SURVIVAL; IPILIMUMAB; TUMORS; CARE;
D O I
10.3389/fonc.2023.1043683
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The growing availability of clinical real-world data (RWD) represents a formidable opportunity to complement evidence from randomized clinical trials and observe how oncological treatments perform in real-life conditions. In particular, RWD can provide insights on questions for which no clinical trials exist, such as comparing outcomes from different sequences of treatments. To this end, process mining is a particularly suitable methodology for analyzing different treatment paths and their associated outcomes. Here, we describe an implementation of process mining algorithms directly within our hospital information system with an interactive application that allows oncologists to compare sequences of treatments in terms of overall survival, progression-free survival and best overall response. As an application example, we first performed a RWD descriptive analysis of 303 patients with advanced melanoma and reproduced findings observed in two notorious clinical trials: CheckMate-067 and DREAMseq. Then, we explored the outcomes of an immune-checkpoint inhibitor rechallenge after a first progression on immunotherapy versus switching to a BRAF targeted treatment. By using interactive process-oriented RWD analysis, we observed that patients still derive long-term survival benefits from immune-checkpoint inhibitors rechallenge, which could have direct implications on treatment guidelines for patients able to carry on immune-checkpoint therapy, if confirmed by external RWD and randomized clinical trials. Overall, our results highlight how an interactive implementation of process mining can lead to clinically relevant insights from RWD with a framework that can be ported to other centers or networks of centers.
引用
收藏
页数:11
相关论文
共 45 条
  • [1] Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
    Atkins, Michael B.
    Lee, Sandra J.
    Chmielowski, Bartosz
    Tarhini, Ahmad A.
    Cohen, Gary I.
    Truong, Thach-Giao
    Moon, Helen H.
    Davar, Diwakar
    O'Rourke, Mark
    Stephenson, Joseph J.
    Curti, Brendan D.
    Urba, Walter J.
    Brell, Joanna M.
    Funchain, Pauline
    Kendra, Kari L.
    Ikeguchi, Alexandra P.
    Jaslowski, Anthony
    Bane, Charles L.
    Taylor, Mark A.
    Bajaj, Madhuri
    Conry, Robert M.
    Ellis, Robert J.
    Logan, Theodore F.
    Laudi, Noel
    Sosman, Jeffrey A.
    Crockett, David G.
    Pecora, Andrew L.
    Okazaki, Ian J.
    Reganti, Sowjanya
    Chandra, Sunandana
    Guild, Samantha
    Chen, Helen X.
    Streicher, Howard Z.
    Wolchok, Jedd D.
    Ribas, Antoni
    Kirkwood, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 186 - +
  • [2] Dashboard Design Patterns
    Bach B.
    Freeman E.
    Abdul-Rahman A.
    Turkay C.
    Khan S.
    Fan Y.
    Chen M.
    [J]. IEEE Transactions on Visualization and Computer Graphics, 2023, 29 (01) : 342 - 352
  • [3] Real-world data: towards achieving the achievable in cancer care
    Booth, Christopher M.
    Karim, Safiya
    Mackillop, William J.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (05) : 312 - 325
  • [4] Business Process Management Workshops - BPM, 2011, BUSINESS PROCESS MAN
  • [5] BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
    Colombino, Maria
    Capone, Mariaelena
    Lissia, Amelia
    Cossu, Antonio
    Rubino, Corrado
    De Giorgi, Vincenzo
    Massi, Daniela
    Fonsatti, Ester
    Staibano, Stefania
    Nappi, Oscar
    Pagani, Elena
    Casula, Milena
    Manca, Antonella
    Sini, MariaCristina
    Franco, Renato
    Botti, Gerardo
    Caraco, Corrado
    Mozzillo, Nicola
    Ascierto, Paolo A.
    Palmieri, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) : 2522 - 2529
  • [6] Cuendet MA., 2021, SYST MED, V2, P342, DOI [10.1016/B978-0-12-801238-3.11704-0, DOI 10.1016/B978-0-12-801238-3.11704-0]
  • [7] Dagliati Arianna, 2018, J Diabetes Sci Technol, V12, P251, DOI 10.1177/1932296818761751
  • [8] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [9] fda, ABOUT US
  • [10] Gatta R., 2017, PMINER INNOVATIVE R